Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gabriele Minuti

Showing results (31-40 of 47) with videos related to

Pageof 5
Sort By:
JAMA Oncology|May 22, 2025
Neoadjuvant PD-1 and PD-L1 Blockade With Chemotherapy for Borderline Resectable and Unresectable Stage III Non-Small Cell Lung CancerBiagio Ricciuti, Francesca Fusco, Alissa Cooper, et al.
Frontiers in Oncology|March 4, 2026
Real-world description of patients with resected epidermal growth factor receptor mutation positive non-small cell lung carcinoma treated with adjuvant osimertinib in an early access program in Italy: the ELBA observational studyGiulia Pasello, Claudia Proto, Carlo Genova, et al.
Journal of Translational Medicine|October 16, 2023
The Molecular Tumor Board of the Regina Elena National Cancer Institute: from accrual to treatment in real-worldPatrizio Giacomini, Fabio Valenti, Matteo Allegretti, et al.
Lung Cancer (Amsterdam, Netherlands)|December 29, 2023
Sotorasib in KRASp.G12C mutated advanced NSCLC: Real-world data from the Italian expanded access programFrancesco Passiglia, Maria Lucia Reale, Giuseppe Lo Russo, et al.
Lung Cancer (Amsterdam, Netherlands)|September 30, 2025
Advanced-stage ALK-positive non-small-cell lung cancer (NSCLC) patients: Real-world treatment patterns and outcomes from the Italian biomarker ATLAS databaseMaria Lucia Reale, Daniela Scattolin, Antonio Vitale, et al.
European Journal of Cancer (Oxford, England : 1990)|December 31, 2025
Braf-mutant metastatic non-small-cell lung cancer: Real world data from the Italian biomarker atlas databaseClaudio Sini, Alessandro Russo, Diego Cortinovis, et al.
The Oncologist|December 24, 2025
Adjuvant atezolizumab in surgically resected NSCLC patients with PD-L1 expression ≥50%: real-world data from the italian ATLAS registryFrancesco Passiglia, Maria Lucia Reale, Giulia Pasello, et al.
Cancer|May 30, 2026
Amivantamab in advanced non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations: Real-world data from the Italian ATLAS RegistryFrancesco Passiglia, Antonio Passaro, Eleonora Gariazzo, et al.
The Lancet. Oncology|June 17, 2020
COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort studyMarina Chiara Garassino, Jennifer G Whisenant, Li-Ching Huang, et al.
European Journal of Cancer (Oxford, England : 1990)|March 15, 2021
Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world studyAlessio Cortellini, Katia Cannita, Marcello Tiseo, et al.
Pageof 5

Showing results (31-40 of 47) with videos related to

Sort By:
Pageof 5
JAMA Oncology|May 22, 2025
Neoadjuvant PD-1 and PD-L1 Blockade With Chemotherapy for Borderline Resectable and Unresectable Stage III Non-Small Cell Lung CancerBiagio Ricciuti, Francesca Fusco, Alissa Cooper, et al.
Frontiers in Oncology|March 4, 2026
Real-world description of patients with resected epidermal growth factor receptor mutation positive non-small cell lung carcinoma treated with adjuvant osimertinib in an early access program in Italy: the ELBA observational studyGiulia Pasello, Claudia Proto, Carlo Genova, et al.
Journal of Translational Medicine|October 16, 2023
The Molecular Tumor Board of the Regina Elena National Cancer Institute: from accrual to treatment in real-worldPatrizio Giacomini, Fabio Valenti, Matteo Allegretti, et al.
Lung Cancer (Amsterdam, Netherlands)|December 29, 2023
Sotorasib in KRASp.G12C mutated advanced NSCLC: Real-world data from the Italian expanded access programFrancesco Passiglia, Maria Lucia Reale, Giuseppe Lo Russo, et al.
Lung Cancer (Amsterdam, Netherlands)|September 30, 2025
Advanced-stage ALK-positive non-small-cell lung cancer (NSCLC) patients: Real-world treatment patterns and outcomes from the Italian biomarker ATLAS databaseMaria Lucia Reale, Daniela Scattolin, Antonio Vitale, et al.
European Journal of Cancer (Oxford, England : 1990)|December 31, 2025
Braf-mutant metastatic non-small-cell lung cancer: Real world data from the Italian biomarker atlas databaseClaudio Sini, Alessandro Russo, Diego Cortinovis, et al.
The Oncologist|December 24, 2025
Adjuvant atezolizumab in surgically resected NSCLC patients with PD-L1 expression ≥50%: real-world data from the italian ATLAS registryFrancesco Passiglia, Maria Lucia Reale, Giulia Pasello, et al.
Cancer|May 30, 2026
Amivantamab in advanced non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations: Real-world data from the Italian ATLAS RegistryFrancesco Passiglia, Antonio Passaro, Eleonora Gariazzo, et al.
The Lancet. Oncology|June 17, 2020
COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort studyMarina Chiara Garassino, Jennifer G Whisenant, Li-Ching Huang, et al.
European Journal of Cancer (Oxford, England : 1990)|March 15, 2021
Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world studyAlessio Cortellini, Katia Cannita, Marcello Tiseo, et al.
Pageof 5